近日，鱼跃医疗（002223）与复旦大学附属妇产科医院(又称"上海市红房子妇产科医院")举行临床研究合作签约 仪式。双方将聚焦妊娠期、新生儿期、更年期及妇科围手术期等重点人群的血糖管理，联合开展系列前沿临床研 究，旨在提升相关健康问题的精准防治水平，助力妇女儿童全周期健康管理。 鱼跃医疗董事长吴群表示，此次合作是前沿技术与临床需求相结合的重要探索，具有积极的社会意义。希望通过 扎实的临床研究，为母婴健康守护和女性特定生命阶段代谢管理提供科学支持，并将研究成果转化为临床实践， 提升健康管理水平。他还提到，合作有助于验证持续动态血糖监测产品在复杂临床场景中的可靠性与适用性，为 产品迭代创新注入临床动力。企业将持续携手顶尖医疗机构，构建产学研协同生态，共同探索数字化、个性化健 康管理新路径。 复旦大学附属妇产科医院院长姜桦表示，医院长期致力于妇女儿童全生命周期健康事业，此次与鱼跃医疗的合作 是医工交叉、科研与产业转化相结合的有益尝试。双方将共同推动精准血糖管理在妇产科领域的深入应用，促进 前沿科研资源转化为临床价值。 此次合作标志着国内医疗器械企业与高水平专科医院在专科健康领域协同创新取得新进展。双方表示，将共同推 ...

截至2025年10月30日，倍轻松已在全国范围内打造15家"轻松一刻"门店。目前重点聚焦深圳，并已覆盖 广州、西安、重庆、成都等城市，成效初显。此外，"轻松一刻"通过团购模式切入企业服务领域，为企 业员工提供速效按摩服务，帮助其在忙碌工作中获得片刻放松。未来公司还将根据情况增设更多门店， 旨在进一步融合科技与服务优势，拓展市场版图，增强品牌全球影响力。 在巩固国内市场的同时，倍轻松也在积极扩大国际市场的版图。倍轻松介绍，公司早在2010年就开始探 索海外市场，从日韩等亚太市场做起，之后辐射到欧美等区域市场。多年来，公司坚持全球化布局的发 展战略，为积极拓展海外市场，公司投资设立了香港倍轻松、美国倍轻松和日本倍轻松等子公司，在海 外通过亚马逊、TikTok、Shopee、Lazada等国际平台设立线上直营店、海外独立站等。2024年公司在海 外实现营收7987.05万元，同比增长9.49%，成为公司业绩新增长点。 国信证券研报显示，倍轻松系我国高端局部按摩仪龙头，受当前消费形势影响，公司经营有所承压。但 公司积极探索新业务模式、发力海外等新渠道、拓展新品类，后续变革成效有望释放，带动收入和业绩 迎来企稳修复。 ...

本报讯 （记者刘晓一）12月26日，深圳市倍轻松科技股份有限公司（以下简称"倍轻松"）召开职工代 表大会，选举公司研发中心副总监、分管AI与软件部门的核心技术人员李华为第六届董事会职工代表 董事，任期至第六届董事会任期届满。 渠道革新与全球化布局成为增长新引擎。线下方面，公司推出"轻松一刻"健康管理品牌，将门店升级 为"科技产品+速效按摩"复合模式，构建"智能设备+人工手法+艾灸理疗"三位一体服务体系，截至2025 年10月30日已在深圳、广州、西安等城市布局15家门店，并通过团购模式切入企业服务领域。 海外市场布局成效显著。自2010年起，倍轻松从日韩市场逐步辐射至欧美及东南亚区域，通过设立中国 香港、美国、日本等子公司，借助亚马逊、TikTok等国际平台搭建线上渠道，2024年海外营收达 7987.05万元，同比增长9.49%。 国信证券研报指出，尽管受消费形势影响经营承压，但倍轻松通过探索新业务模式、发力海外渠道、拓 展新品类，有望推动业绩企稳修复。据弗若斯特沙利文预测，2029年中国按摩市场规模将超6000亿元， 倍轻松凭借综合优势有望充分受益行业增长红利。 （编辑 张昕） 作为智能便携按摩器具行业龙 ...

11月15日的青岛，寒意初显，但一汽解放（000800）青岛汽车有限公司的即墨厂区内却暖流涌动。一场 名为"扬帆家年华.领航新乐章"的2025员工家属开放日暨员工音乐节正在这里温情上演。 健康理念的温暖延伸 此次如新的亮相，并非一次孤立的品牌展示，而是其"善行健康领跑社区"年度健康科普活动的一次极具 代表性的场景深化。该活动自今年3月启动以来，便以深入社区、联动全国体验店和沙龙为核心模式。 而今，如新将这一健康快车开进一汽解放青汽的厂区，正是将其成熟的健康科普网络，成功拓展至大型 企业"'家'文化与工业文化深度融合"的场景之中。 在钢铁机械与现代生产线构成的"工业风"背景中，一个充满活力与温度的展位格外引人注目——作为本 次活动友好品牌亮相的如新(中国)所设立的"善行健康"体验区。这不仅是一个展位，更是一座桥梁，将 企业对员工的关怀，延伸至对其家庭健康的深切关爱。 从"厂区"到"社区" 如新集团首席产品执行副总裁贺杰德指出："在大健康产业蓬勃发展的背景下，我们确立了清晰的战略 方向——以基因表达科技、人工智能与大数据为驱动，深耕抗衰老、代谢健康及认知健康三大核心领 域。"2025年，正是如新的创新成果集中呈现 ...

Core Viewpoint - The forum on "Technology Empowering a Healthy Future" aligns with the national strategy of promoting "Healthy China" and emphasizes the importance of collaboration among various stakeholders in the health industry [1][4]. Group 1: Industry Insights - The health industry in China is experiencing continuous market expansion, with health-related products and services becoming essential consumer needs. The "Healthy China 2030" plan aims for the total scale of the health service industry to reach 16 trillion yuan by 2030 [7]. - The average lifespan of individuals has increased significantly over the past century, attributed to improved living conditions, nutrition, and the role of small molecule drugs in disease treatment [7]. - The forum highlighted the critical role of technological breakthroughs in the prosperity of the industry, with a focus on making scientific advancements accessible to the public and contributing to long-term national and social development [7][8]. Group 2: Company Developments - Qianqingyuan, a biotechnology company focused on molecular gene science, aims to transform research outcomes into anti-aging solutions that benefit the public [7]. - The company has achieved significant milestones in its research on HGHI (Health Gene Health Initiative) over the past decade, positioning itself to empower healthier lifestyles through technology [8]. - A health action initiative titled "Building a Long-lasting Industry with Health" was launched by multiple company representatives at the forum, reflecting a commitment to health principles and collaboration within the industry [8][11].

Investment Rating - The investment rating for the company is "Outperform the Market" [5][3]. Core Insights - The company is experiencing ongoing operational pressure, with a significant decline in revenue and net profit for the first three quarters of 2025. Revenue decreased by 34.1% to 550 million, and net profit fell to -70 million, a decline of 601.0% [1]. - The company is actively exploring new growth opportunities by transforming its offline stores into a new model combining "technology products + quick-effect massage," launching the "Light Relaxation Moment" health management brand, and leveraging innovative technologies in product development [2][3]. - The gross profit margin has decreased by 5.9 percentage points to 60.9% in Q3, indicating pressure on profitability due to fixed costs and declining revenues [3]. Financial Performance Summary - For 2025, the company is projected to have a total revenue of 835 million, a decrease of 23.1% year-on-year, with a net profit of -54 million, reflecting a significant decline of 622.3% [4][26]. - The company anticipates a gradual recovery in revenue and profitability from 2026 onwards, with expected net profits of 25 million in 2026 and 48 million in 2027, indicating a turnaround [4][25]. - The company’s PE ratio is projected to be -48.1 for 2025, reflecting the current challenging operating environment [4][27].

Investment Rating - The investment rating for the company is "Outperform the Market" [5][3]. Core Views - The company is experiencing ongoing operational pressure, with a significant decline in revenue and net profit for the first three quarters of 2025. Revenue decreased by 34.1% to 550 million, and net profit dropped by 601.0% to -70 million. The third quarter alone saw a revenue decline of 28.5% to 170 million, with net profit losses expanding [1][3]. - The company is actively exploring new growth opportunities by transforming its offline stores into a new model that combines "technology products + quick-effect massage." The launch of the "Light Relaxation Moment" health management brand aims to enhance customer traffic and revenue [2][3]. - The company's gross margin has decreased by 5.9 percentage points to 60.9% in Q3, with rising expense ratios impacting profitability. The net profit margin for Q3 fell by 12.1 percentage points to -17.7% [3][4]. Financial Performance Summary - For 2025, the company is projected to have a total revenue of 835 million, a decrease of 23.1% year-on-year. The net profit is expected to be -54 million, reflecting a significant decline of 622.3% [4][26]. - The company anticipates a gradual recovery in revenue and profitability from 2026 onwards, with projected net profits of 25 million in 2026 and 48 million in 2027, indicating a turnaround [4][25]. - The company’s gross margin is expected to stabilize around 60% from 2025 to 2027, while the net profit margin is projected to improve as new business models and products are rolled out [20][23].

Core Insights - The company views China as its most strategically significant market and innovation hub, emphasizing plans for increased investment in Shanghai to meet local consumer demands [1][2] Group 1: Capacity and Talent Development - Capacity construction is a key foundation for the company's development in China, with the second phase of the Greater China Innovation Headquarters Park set to enhance production efficiency through a fully automated system [2] - The company plans to expand its Shanghai production base to better meet health product demands in China and globally, aiming for "Chinese intelligence" to serve global consumers [2] - Talent development initiatives include expanding the "Nutrition Health Consultant" program to cultivate skilled professionals in health management, promoting local collaboration to integrate global technology with local needs [2] Group 2: Health Technology - The company aligns with the "Healthy China 2030" strategy, launching the TRME body management plan that utilizes ageLOC gene technology for sustainable metabolic improvement [3] - Increased investment in cognitive health research is planned for 2025, with the PRYSM iO hyperspectral scanner providing rapid, non-invasive health assessments to guide lifestyle improvements [3] - The integration of these technological advancements aims to create a comprehensive solution system for health empowerment [3] Group 3: Sustainable Development - Digital transformation and green development are two additional strategic focuses, with a partnership with Alibaba Cloud initiated in 2017 to enhance digital capabilities [4] - The company has implemented a green commitment across its entire supply chain, as outlined in its ESG report, to explore paths for sustainable development in the health industry [4] - Future plans include deepening local innovation, expanding capacity, and upgrading digital services to contribute to the development of China's health industry [4]

Group 1 - The company plans not to distribute profits for the first half of 2025, including no cash dividends or stock bonuses, to ensure sustainable development and protect long-term shareholder interests [4] - The board of directors confirmed the authenticity, accuracy, and completeness of the half-year report, which has not been audited [3][6] - The company reported an unallocated profit of -41,204,869.29 yuan as of June 30, 2025, indicating that the unallocated losses exceed one-third of the paid-in capital [17] Group 2 - The company has faced challenges due to macroeconomic fluctuations, structural changes in consumer behavior, and intensified industry competition, leading to cautious spending among high-income consumers [18] - The company is implementing strategic adjustments focused on "technology empowering health," leveraging its strengths in traditional Chinese medicine and technology to enhance brand loyalty and consumer experience [19] - The company is pursuing a global strategy to expand into emerging markets and key channels, aiming to build a diverse and robust international business system [19] Group 3 - The company raised 422.23 million yuan through its initial public offering, with a net amount of 358.91 million yuan after deducting fees [22][23] - As of the reporting period, the company had a remaining balance of 57.54 million yuan in raised funds, primarily due to ongoing projects [23][27] - The company has established a management system for raised funds, ensuring compliance with relevant laws and regulations [25][26]

Core Insights - The company reported a decline in both revenue and net profit for the first half of 2025, with revenue at 385 million yuan, down 36.22% year-on-year, and a net loss of 36.11 million yuan, down 238.19% year-on-year [3][4] - The company has experienced 11 consecutive quarters of losses since 2022, with the last four quarters also showing negative results [10] - The company announced that its unremedied losses have reached one-third of its paid-in capital, necessitating a temporary shareholders' meeting as per company law [6][7] Financial Performance - In Q2, the company’s revenue was 188 million yuan, a year-on-year decline of 39.42%, with a net loss of 34.28 million yuan, down 425.76% year-on-year [4] - The overall gross margin improved to 62.63%, an increase of 0.81 percentage points compared to the same period last year, attributed to cost reduction efforts [4] - Sales expenses decreased by 27.15% to 216 million yuan, with promotional expenses dropping by 43.65% from 114 million yuan to 63.73 million yuan [4] Cash Flow and Operational Challenges - Cash received from sales and services fell to 440 million yuan, down 36.08% year-on-year, leading to a negative net cash flow from operating activities of 20.87 million yuan, a decrease of 135.32% [5][6] - The company cited macroeconomic fluctuations, structural changes in consumer behavior, and intensified industry competition as primary reasons for its financial struggles [7] Strategic Initiatives - The company aims to leverage technology in health, promoting a "Chinese medicine × technology" strategy, and plans to enhance its overseas market presence [11][12] - Despite these initiatives, revenue from high-end products has been under pressure, with significant declines across various product categories [12][13] - The overseas business also faced challenges, with revenue down 39.32% to 19.87 million yuan and a gross margin decrease of 2.48 percentage points [13]